GlassScriptPhysician profile
Joseph N Hall
NPI 1649231200
$16,981.74
in general payments reported to CMS, 2019-2025
26 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,316 · 2020: $8,902 · 2021: $3,218 · 2022: $1,507 · 2023: $317 · 2024: $454 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $7,414.82 | 2019-2020 | |
| Nextremity Solutions INC. | $4,856.51 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $2,244.19 | 2019-2025 | Tapestry, Stratum Foot Plating System, Incore Lapidus |
| Stryker Corporation | $483.91 | 2021-2024 | Ortholoc 2 Lapifuse |
| Paragon 28, INC. | $292.84 | 2020-2024 | Phantom Intramedullary Nail, Precision Guide Lapidus, Bun-Yo-Matic |
| Horizon Therapeutics Plc | $235.62 | 2019-2022 | |
| Treace Medical Concepts, INC. | $198.11 | 2022 | |
| Kerecis Limited | $186.77 | 2022 | |
| Smith+Nephew, INC. | $182.95 | 2019-2025 | Grafix, Stravix, Grafix Pl |
| Invictus Surgical Incorporated | $181.72 | 2024-2025 | |
| Organogenesis INC. | $167.07 | 2020-2024 | |
| Zimvie INC. | $84.53 | 2022 | |
| Mimedx Group, INC. | $65.89 | 2025 | |
| Bioventus LLC | $52.76 | 2020-2024 | Exogen Ultrasound Bone Healing System |
| Biowound Solutions, INC. | $44.57 | 2025 | Bio-Connekt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $44.27 | 2019-2021 | |
| Nevro Corp. | $43.59 | 2022-2024 | Senza |
| Medline Industries LP | $41.58 | 2019 | |
| Medartis INC. | $25.57 | 2022 | |
| Depuy Synthes Sales INC. | $22.66 | 2024 | Na |
| Next Science LLC | $21.91 | 2023 | Surgx, Xperience, Blastx |
| Arthrosurface Incorporated | $20.33 | 2019 | |
| Medtronic, INC. | $19.60 | 2021 | |
| Fidia Pharma USA INC. | $19.08 | 2024 | Hyalgan, Hymovis, Triluron |
| Medtronic Vascular, INC. | $16.86 | 2020 | |
| Sandoz INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.